cTRP Scaffold-Based SARS-CoV-2 Vaccine Antigen Presentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current SARS-CoV-2 vaccines face challenges due to waning immunity, biological and behavioral diversity, and emergence of viral variants, leading to ongoing pandemic risks and potential future outbreaks.
Innovation Solution
Development of SARS-CoV-2 vaccines that present antigens as trimers or tetramers on a circular tandem repeat protein (cTRP) scaffold, enhancing immunogenicity, expression, and stability, and allowing for subunit protein or DNA/mRNA administration to induce immune responses and treat or prevent infection symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current SARS-CoV-2 vaccines are used, then initial immunity is provided, but immunity wanes over time and fails to prevent future outbreaks
Solution Approach 1:
The patent changes the structural parameters of the vaccine antigen by presenting SARS-CoV-2 spike antigens as trimers or tetramers on a circular tandem repeat protein (cTRP) scaffold. This structural modification enhances immunogenicity and extends immunity duration, resolving the contradiction between initial efficacy and long-term protection.
Solution Approach 2:
The patent creates a composite vaccine structure by combining the SARS-CoV-2 spike antigen with the cTRP scaffold. This composite approach integrates the immunogenic properties of the viral antigen with the stabilizing and immunomodulating properties of the cTRP scaffold, achieving both high initial efficacy and extended duration of action.
2Adaptability or versatility
If vaccines are administered to diverse populations, then coverage is expanded, but biological and behavioral diversity reduces vaccine effectiveness
Solution Approach 1:
The cTRP scaffold provides universal immunogenic properties that function effectively across diverse biological populations. The scaffold's structure enables it to elicit robust immune responses regardless of individual biological variations, achieving both broad population coverage and consistent effectiveness.
3Adaptability or versatility
If viral variants emerge, then viral evolution occurs, but existing vaccines fail to challenge variant efficacy
Solution Approach 1:
The patent modifies the antigen presentation parameters by using the cTRP scaffold to display viral antigens in a standardized, highly immunogenic configuration. This structural standardization allows the vaccine to maintain efficacy against viral variants by presenting conserved antigenic determinants in an optimized format that elicits broadly neutralizing antibodies.
4Ease of manufacture
If conventional vaccine structures are used, then production is established, but immunogenicity and stability are insufficient
Solution Approach 1:
The patent changes the structural parameters of the vaccine antigen from conventional monomeric or simple multimeric forms to trimers or tetramers on a cTRP scaffold. This structural parameter change enhances both immunogenicity and stability while maintaining production feasibility through established protein expression and purification technologies.
Data Source
AI summary
SARS-CoV-2 vaccines are described herein. The SARS-CoV-2 vaccine antigens can be presented on a circular tandem repeat protein (cTRP) scaffold as trimers or tetramers. The vaccines can be used to treat and/or reduce the risk of SARS-CoV-2 infection and to treat and/or reduce the risk of side effects associated with SARS-CoV-2 infection, such as SARS-CoV-2-related symptoms, syndromes, and complications.